- Conditions
- HIV, Tuberculosis
- Interventions
- Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 171
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Prevention
- Interventions
- bictegravir
- Drug
- Lead sponsor
- Fenway Community Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Hepatitis B
- Interventions
- TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more
- Conditions
- HBeAg-positive Chronic Hepatitis B
- Interventions
- TAF, TDF, TAF Placebo, TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
- Conditions
- Healthy Volunteer, HIV Prevention
- Interventions
- tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV-1-infection
- Interventions
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
- Drug
- Lead sponsor
- The Crofoot Research Center, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Transplant, Hepatitis B
- Interventions
- Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatitis B, Chronic
- Interventions
- JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil, Tenofovir alafenamide, JNJ-56136379
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Bakersfield, California • Palm Springs, California • San Diego, California + 7 more
- Conditions
- HIV
- Interventions
- FTC/TAF
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 14 Years to 100 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir/emtricitabine/tenofovir alafenamide
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- HIV-1-infection
- Interventions
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 9
- States / cities
- Florida City, Florida • Ft. Pierce, Florida • West Palm Beach, Florida + 5 more
- Conditions
- HIV-1
- Interventions
- DRV/COBI FDC placebo tablet, D/C/F/TAF FDC placebo tablets
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 687 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
- Conditions
- HIV-1 Infection
- Interventions
- Lenacapavir, Placebo, B/F/TAF, TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Sacramento, California • Torrance, California + 7 more
- Conditions
- Safety Issues
- Interventions
- TAF/EVG vaginal insert, Matching Placebo vaginal insert
- Drug
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- HIV Infections
- Interventions
- GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir, Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more
- Conditions
- HIV, HIV Infections, Acquired Immunodeficiency Syndrome
- Interventions
- TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Interventions
- ISL, ULO, BIC/FTC/TAF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 11
- States / cities
- San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- bictegravir/emtricitabine/tenofovir alafenamide
- Drug
- Lead sponsor
- Midland Research Group, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Oakland Park, Florida
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF, E/C/F/TDF, ATV, RTV, FTC/TDF, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 29
- States / cities
- Stamford, Connecticut • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 22 more
- Conditions
- Acute HIV Infection
- Interventions
- Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Hepatitis C, HIV Coinfection
- Interventions
- TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
- Interventions
- Doravirine 100 Mg
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Dallas, Texas